Compugen (CGEN) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Jefferies Remains Bullish on Compugen (CGEN) - PT to $9
February 11, 2016 9:46 AM ESTJefferies maintained a Buy rating on Compugen (NASDAQ: CGEN), and cut the price target to $9.00 (from $11.00). CGEN's drug discovery platform has yielded 11 novel immune checkpoint candidate targets, plus five targets for antibody-drug conjugates (ADCs) and four linked to tumour-associated macrophages (TAMs). Jefferies... More
